The most precious gift any parent can currently give to their children is to REMOVE them from public schools. Federal health agencies authorized the updated booster for people ages 12 and older in September and for anyone over 6 months in December. Overall, symptoms were more frequent in people ages 1264 years compared to people ages 65 years and older and more frequent after dose 2 than dose 1 of the primary series. These intervals continue to be recommended for people who are moderately or severely immunocompromised, adults ages 65 years and older, and in situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about COVID-19 community levelsor an individuals higher risk for severe disease). This site uses different types of cookies. Experts view clinical recovery, including return to baseline cardiac function, as an important factor when considering COVID-19 vaccination. A booster dose refers to a single dose of a COVID-19 vaccine given after the protection provided by the primary dose (s) has begun to decrease over time. Currently, a booster dose using any COVID-19 vaccine is not authorized for children in this age group who complete a 3-dose Pfizer-BioNTech primary series, regardless of which Pfizer-BioNTech vaccine (i.e., a monovalent or bivalent) was administered for the third primary series dose. CDC twenty four seven. Pfizer/BioNTech needs to be stripped of all protections against law suits. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for use as a single booster dose in individuals 5 years of age and older at least two months after Each day, every update from those retro baits made my HEAD EXPLODE. A positive anti-nucleocapsid antibody test result indicates prior SARS-CoV-2 infection. Product-specific information is available from CDC. Immunity provided by a booster typically starts to wear off about five or six months after the jab. By July, Biden tapped by Obama to manage the outbreak, gave orders to STOP COLLECTING DATA on the numbers of infections. Children age 5 years: A 3-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. Children age 5 years: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. But, Chin-Hong added, "There are a lot of caveats, meaning that maybe some immunocompromised individuals are older and may need a booster more frequently.". See Appendix Afor additional information on Janssen COVID-19 Vaccine. In general, aspirin is not recommended for use in children and adolescents ages 17 years and younger as an antipyretic or analgesic due to the risk of Reyes syndrome. Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and have also been reported during post-authorization use outside the United States. A conversation between the patient and/or their guardian(s) and their clinical team or a specialist (e.g., infectious diseases, rheumatology, and/or cardiology) is strongly encouraged to assist with decisions about the use of COVID-19 vaccines in the setting of MIS-C or MIS-A. People who are immunocompromised or who have recently had procedures that could disrupt their immune system should ask their doctor about additional bivalent booster shots and whether thats something they could benefit from, Chin-Hong said. Children ages 6 months4 years: A 2-dose primary series and 1 bivalent Moderna booster dose is recommended. We won't be able to respond to every question personally, but what you share with us will help us make our coverage more useful and relevant to you and the people you know. See Appendices B (People who received COVID-19 vaccine outside the United States) and C (People who received COVID-19 vaccine as part of a clinical trial) for recommendationsfor these populations. Systemic reactions include fever, fatigue/malaise, headache, chills, myalgia, arthralgia; among younger children, particularly those younger than ages 3 years, systemic reactions also can include irritability/crying, sleepiness, and loss of appetite. The Omicron-adapted vaccine is currently authorized by Person would otherwise not complete the primary series. People ages 18 years and older who completed primary vaccination using any COVID-19. You can stay anonymous if you want to. Pfizer (PFE)/ BioNTech (BNTX) has filed an application to the FDA seeking Emergency Use nod for a booster shot of their Omicron-adjusted COVID shot for children. Thats one for parents and a blow to Gov. As the country enters flu season,health officials are encouragingAmericans to get their flu shot and COVID-19 booster in the same visit. Major pharmacy retailers like CVS and Walgreens say they're offering both Moderna and Pfizer-BioNTech bivalent vaccines, depending on the location. Also, when does the emergency use end and Pfizer-BioNTech become responsible for any damage their vaccine might do? Periodically, we must employ comment moderation due to an influx of spammers. In fact, the viral outbreak during the Obama years posed a FAR greater threat to children than Covid. In rare instances, administration of certain combination vaccinesor more than one vaccine at the same clinic visit has been associated with an increased risk of febrile seizures in infants and young children. You can review and change the way we collect information below. Administration of COVID-19 vaccines should not be delayed in patients taking immunosuppressive therapies. For the majority of people who have been infected with COVID already, that experience provides them with a layer of immunity also. Because of my prior research during Obamas DACA years, proved to me the CDC and FDA does NOT work for the interests of the American people. The Pfizer booster shot contains a full dose of the regular vaccine, or 30 micrograms. A Pfizer booster is one full dose of Pfizer vaccine, according to the FDA. In January, an FDA committee met to discuss simplifying the COVID vaccine schedule to a single annual dose for most people. FDA authorization allows for dosing optionsfor certain other situations when a child ages from a younger to older age group for Moderna and Pfizer-BioNTech COVID-19 vaccines. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers. The authors explain: In this study, we estimated effectiveness starting from day 7 after the third dose, which is similar to the period used to define full vaccination after the second dose. Pfizer is close to submitting data to the Food and Drug Administration on a fourth dose of its COVID-19 vaccine, according to CEO Albert Bourla. As a booster dose, the vaccine is recommended from about 5 months after the last vaccine dose for persons aged 5 years and above. The bivalent mRNA booster dose is administered at least 2 months after completion of the primary series. Among people ages 65 to 85, the Pfizer data suggest that antibody levels against the delta variant after receiving a third dose of vaccine are greater than 11-fold than following a second dose. Person starts but unable to complete a primary series with the same COVID-19 vaccine due to a contraindication. Among adults ages 18 years and older who received the Novavax booster dose, symptoms were more frequently reported after the booster dose than dose 2 of the primary series. Treatment should not be delayed until test results are available. Webof 3 doses, and recommended to be taken 8 weeks apart between doses. All adults can now get a booster if its been six months or longer since their last COVID-19 booster or confirmed infection, whichever is most recent, Minister Butler said. Pfizer/BioNTech applied for emergency use authorization of their Omicron-adapted COVID-19 vaccine in the United States. In the following exceptional situations, a different COVID-19 vaccine may be administered to complete a primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose (no Vaccine Adverse Event Reporting System [VAERS] report is required): The same monovalent vaccine product should be used for all doses in the primary series with the following exception: children ages 6 months4 years who received 2 primary series doses of a monovalent Pfizer-BioNTech vaccine should receive a bivalent Pfizer-BioNTech vaccine as their third primary series dose. History of myocarditis or pericarditis after a dose of an. Moderna's booster is a half dose of the original vaccine, with 50 micrograms of mRNA in it. There will soon be two bivalent vaccines available to people aged 12 and over. Table 1. "One for the flu shot and the other for the COVID shot.". Pfizer and Moderna's bivalent booster both use mRNA technologycombining the original COVID-19 vaccine along with the reformulation targeting theBA.4 and BA.5 versions of the omicron variant. CDC data shows only about 1.5% of eligible Americans have gotten their shot since the rollout. March 1, 2023. With fall in full swing, experts recommend getting a flu shot and COVID booster at the same time. Federal Health and Aged Care Minister Mark Butler announced on Tuesday that the Government has secured an additional three million doses of the formulation, which is in line with recommendations made by Professor Jane Halton AO in the Halton review of COVID-19 vaccine and treatment purchasing and procurement. %PDF-1.6
%
Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies. Pfizer and BioNTech have submitted an application to the US Food and Drug Administration (FDA) for the emergency use of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a booster dose for children aged six months to four years. Some doctors believe the shots should be stopped over cardiac problems associated with the vaccine. The bivalent booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Vocational Nurse Cleopatra Oniya administers the Pfizer booster shot at a COVID vaccination and testing site decorated for Cinco de Mayo at Ted Watkins Memorial Park in Los Angeles on May 5, 2022. the bivalent COVID vaccine booster became available. For more information on patient counseling, see Vaccine Recipient Education. "If everyone got the bivalent booster that they're supposed to do, that's really the most important point.". The authors explain: In this study, we estimated effectiveness starting from day 7 after the third dose, which is similar to the period used to define full vaccination after the second dose. People who are moderately or severely immunocompromised ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive a second (additional) dose using a monovalent mRNA vaccine and 1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech). In accordance withgeneral best practices, routine administration of all age-appropriate doses of vaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications exist at the time of the healthcare visit. It contains 25 mcg of the SARS-CoV-2 BA.4/5 Omicron subvariant spike protein mRNA and 25 mcg of the ancestral strain spike protein mRNA. Three doses of Pfizer and BioNTech s vaccine provide a high level of protection against the omicron variant of the virus that causes Covid-19, the companies The primary series dose and the additional dose are separated by at least 4 weeks. If antibody testing was done, vaccination with the primary series or a booster dose should be completed as recommended regardless of the antibody test result. Experts consider the benefits of COVID-19 vaccination for people with a history of MIS-C/A (i.e., a reduced risk of severe disease including potential recurrence of MIS-C after reinfection) to outweigh a theoretical risk of an MIS-like illness or the risk of myocarditis following COVID-19 vaccination for those who meet the following two criteria: COVID-19 vaccination may also be considered for people who had MIS-C/A anddo not meet both criteria, at the discretion of their clinical care team (see Consultation for decisions about COVID-19 vaccination). Also, a low risk of reinfection has been observed in the weeks to months following infection. 6 l> We've also left space for you to tell us anything you want to share about how COVID has affected your life. For people who have a history of myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A. Follow Adrianna Rodriguez on Twitter: @AdriannaUSAT. For the primary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at least 4 weeks. We dont know what those spike proteins are doing, but changing DNA is bad. People ages 12 years and older: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. CDC is monitoring for febrile seizures following COVID-19 vaccination in infants and young children. Answer: Bivalent boosters combine the original COVID-19 vaccine with a reformulation that targets the BA.4 and BA.5 versions of the omicron variant. "If you've gotten the primary series, you have protection from serious disease, hospitalization and death for at least a year probably even longer for most people," he said. Children ages 611 years: A 2-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. Marketing cookies are used to track visitors across websites. Its given as a full dose - the same as for the first and second doses. These clinical considerations provide information to healthcare professionals and public health officials on use of COVID-19 vaccines. Pfizer is close to submitting data to the Food and Drug Administration on a fourth dose of its COVID-19 vaccine, according to CEO Albert Bourla. Antibody testing is not currently recommended to assess the need for vaccination in an unvaccinated person or to assess immunity to SARS-CoV-2 following COVID-19 vaccination. The Biden administration also urges Americans to take advantage of its vaccine locator website, vaccines.gov. ", Boosters forkids:Pfizer-BioNTech asks FDA to authorize new omicron-targeting COVID booster for children 5 to 11. *A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and older who completed a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. People with a history of a non-severe, immediate (onset less than 4 hours) allergic reaction after a dose of, Moderate or severe acute illness, with or without fever. The BA.5 strainisthe predominant variantcirculating the country, making up more than 85% of new COVID-19 cases in the U.S., according to the CDC. As of January 26, 2023, tixagevimab/cilgavimab (EVUSHELD), a combination of two monoclonal antibodies, is not currently authorized for use in the United States. For best practices for administering multiple injections, see ACIPs general best practicesandEpidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). Currently, a booster dose using any COVID-19 vaccine is not authorized for children in this age group who complete a 3-dose Pfizer-BioNTech primary series, regardless of which Pfizer-BioNTech vaccine (i.e., a monovalent or bivalent) was administered for the third primary series dose. If you dont see your language, email sara@independentsentinel.com we will add it. For guidance on vaccination in specific situations, seeTransitioning from a younger to older age group,Considerations for extended intervals for COVID-19 vaccineprimary series doses, andCOVID-19 vaccination and SARS-CoV-2-infection. NEW YORK and MAINZ, GERMANY, March 1, 2023 Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a booster (fourth) dose of the companies Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 If you need help making a COVID-19 vaccine booking, SMS Hey EVA to 0481 611 382. CDC guidance says FDA-authorized boosters can be mixed and matched after completing a primary series. Bivalent mRNA vaccines are not authorized at this time for primary series doses with the following exception: children ages 6 months4 years who receive 2 primary series doses of a monovalent Pfizer-BioNTech vaccine should receive a bivalent Pfizer-BioNTech vaccine as their third primary series dose. Both the original COVID-19 vaccines and the updated bivalent boosters use messenger RNA technology. Anyone who is currently eligible to receive a first or second Studies have shown that increased time between infection and vaccination might result in an improved immune response to vaccination. For information on potential use of Janssen COVID-19 Vaccine, see Appendix A. "I really believe this is why God gave us two arms," Jha said during a White House briefing. The primary series doses are separated by 48 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series. But the immune system doesnt start from scratch when a vaccines immunity begins to wane. Pfizer and BioNTech have submitted an application to the US Food and The Pfizer A growing body of evidence on the safety and effectiveness of COVID-19 vaccination indicates that the benefits of vaccination outweigh any potential risks of COVID-19 vaccination during pregnancy. A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used inlimited situationsin people ages 18 years and older who completed any FDA-approved or FDA-authorized monovalent primary series, have not received any previous booster dose(s), and are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. However, providers should not routinely administer doses of COVID-19 vaccine beyond those recommended in this guidance. The formulation officially named Spikevax Bivalent Original/Omicron BA.4-5 (Spikevax Bivalent BA.4/5) has been given the green light for use in people aged 12 years and over who are recommended a COVID-19 booster dose. In addition, people who recently had SARS-CoV-2 infection may consider delaying a primary series dose or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic). The benefit of vaccination outweighs the risks for most people. Those who received antibody products due to a recent SARS-CoV-2 infection should follow the guidance in the section above. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. The U.S. health regulator currently authorizes the People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine, Active treatment for solid tumor and hematologic malignancies, Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia), Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy, Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy), Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome), Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm, Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents), Current or planned immunosuppressive therapies, Optimization of both the patients medical condition and anticipated response to vaccination. An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these COVID-19 vaccines. There is NO WAY I would submit my child as a lab rat for Big Pharma. If, after a risk assessment, the decision is made to administer a subsequent COVID-19 vaccine dose, wait until at least after their episode of myocarditis or pericarditis has resolved (i.e., resolution of symptoms, no evidence of ongoing heart inflammation or sequelae as determined by patients clinical team), Myocarditis or pericarditis considered unrelated to vaccination (e.g., due to SARS-CoV-2 or other viruses), especially if the diagnosis of myocarditis or pericarditis occurred more than 3 weeks after the most recent dose of COVID-19 vaccine, Personal risk of severe acute COVID-19 (e.g., age, underlying conditions), Timing of any immunomodulatory therapies; ACIPs. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose. COVID-19 vaccine products (see Table 1) are formulated as follows: None of the currently FDA-approved or FDA-authorized COVID-19 vaccines are live-virus vaccines. FDA commissioner Dr. Robert Califf said that ifthe agency waited until studies were completed in another month or two, "the (COVID) wave will have passed us by and the damage will have been done. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. (Justin Sullivan/Getty Images) Just 38% of San Franciscans have received the bivalent booster, compared with 86% who completed the initial series, according to data from the The first and second doses are separated by 4 weeks and the second and third doses are separated by at least 4 weeks. Use of the monovalent Novavax booster dose in limited situations, Table 2. Health experts say immunity from the bivalent booster should carry through the holiday season, which will not only protect the person getting vaccinated, but also vulnerable loved ones during family gatherings. The Idea of even applying for an Emergency Use COVID Booster for Toddlers is pure Insanity. CDC recommends that people stay up to date with COVID-19 vaccination by completing a primary series and receiving the most recent booster dose recommended for them by CDC (seeTable 2 and Table 3). Thereporting rates for myocarditis after mRNA COVID-19 primary series vaccination or booster vaccination exceed the background rates in several age groups in males and females with the highest rates observed in males ages 1239 years; see the. ANY parent who surrenders their child as an experiment, IMO, simply is not responsible enough to HAVE children. Tell us and you could see it answered. Gavin Newsom. People who dont have insurance could face new costs after the federal emergency order ends. For primary series vaccination, three monovalent COVID-19 vaccines (listed in alphabetical order by manufacturer), are recommended: Moderna, Novavax, and Pfizer-BioNTech. People ages 12 years and older: A 3-dose primary series and 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. Patients who received monovalent booster dose(s) prior to or during treatment should receive 1 bivalent mRNA booster dose as there is no revaccination for monovalent booster doses. *Illustrations of the different vaccine vial cap and label border colors are available for Moderna andPfizer-BioNTech COVID-19 vaccines. A monovalent vaccine is administered for the first and second doses, which are separated by 3 weeks. We dont know what this does to children, and they really arent dying from COVID-19. For the primary series, the first and second doses are separated by 3 weeks and the second and third doses are separated by at least 4 weeks. A monovalent Pfizer-BioNTech vaccine is used for the first and second primary series doses; a bivalent Pfizer-BioNTech vaccine is used for the third primary series dose. A 2021 study from the CDC found people were over five times more likely to get COVID-19 three to six months after a prior infection if they were unvaccinated, compared with those who were fully vaccinated and were never infected. Do you have a question about COVID? This applies to primary series and booster doses. See COVID-19 vaccination and myocarditis and pericarditisfor additional information. See Appendix A for additional information on Janssen COVID-19 Vaccine. Further to that, early evidence suggests a booster dose of Modernas bivalent BA.4/5 vaccine provides greater protection against hospitalisation and death from severe Omicron disease, at 63.8%, compared to a booster dose of Modernas original vaccine at 13 months in adults, at 38.6%. The FDA Authorized a COVID-19 Booster Shot for Immunocompromised People. So far, 8.8 million Americans have received a booster dose of the Pfizer vaccine. Adverse events that occur in a recipient following COVID-19 vaccination should be reported to VAERS. Health experts are urging Americans to get their bivalent booster as soon as possible. The FDA said study participants who received the bivalent vaccine reported some side effects likepain, redness and swelling at the injection site, fatigue, headache, muscle and joint pain. People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. 2/03/2023 12:03:32 AM, Terms and conditions | Privacy statement | RACGP | recruitGP | AJGP, 2018 The Royal Australian College of General Practitioners (RACGP) ABN 34 000 223 807. Such testing outside of the context of research studies isnot recommended at this time. This includes people with prolonged post-COVID-19 symptoms and applies to primary series and booster doses. Acetaminophen can be offered as an option for pregnant people experiencing fever (fever has been associated with adverse pregnancy outcomes) or other post-vaccination symptoms. (Justin Sullivan/Getty Images) Just 38% of San Franciscans have received the bivalent booster, compared with 86% who completed the initial series, according to data from the People who received Janssen COVID-19 Vaccine after a dose of another COVID-19 vaccine should be considered to have received a valid, single-dose Janssen primary series. See also COVID-19 vaccination and myocarditis and pericarditis and Vaccine reactions and adverse events for Novavax COVID-19 Vaccine. No matter the topic, share your question with us in the Google Form below. Moderna, Novavax, or Pfizer-BioNTech) and the unknown risk for myocarditis and pericarditis after JYNNEOS administration. People who previously received COVID-19 vaccination (i.e. COVID-19 vaccine-specificFDA fact sheets and U.S. COVID-19 Vaccine Product Informationcan be consulted for a full list of ingredients and information on the conditions of use, storage and handling, preparation, and administration procedures. People who have a history of myocarditis or pericarditis unrelated to vaccination with Moderna, Novavax, or Pfizer-BioNTech (e.g., due to SARS-CoV-2 or other viruses) may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved (i.e., resolution of symptoms, no evidence of ongoing heart inflammation or sequelae as determined by the persons clinical team). We'll assume you're ok with this, but you can opt-out if you wish. Fact is, HOME SCHOOLED students have for YEARS been out performing public school students, IN EVERY SUBJECT on standardized tests. The bivalent booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Pfizer Inc and its German partner BioNTech SE have applied for emergency use authorization of their Omicron-adapted COVID-19 vaccine in the United States as a Pfizer-BioNTech COVID-19 Vaccine/COMIRNATY, Janssen (Johnson & Johnson) COVID-19 Vaccine, Monovalent vaccine:The vaccine product is based on the original (ancestral) strain of SARS-CoV-2, Bivalent vaccine:The vaccine product is based on the original (ancestral) strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 (BA.4/BA.5) variants of SARS-CoV-2. What you would get: A third full dose, at least six months after your second. We have a multi-language translator on the top left. For complicated situations, not addressed by the guidance above, healthcare and public health professionals may consider requesting a consultation from theClinical Immunization Safety Assessment COVIDvaxproject.